Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Debt & Financing category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quoin Pharmaceuticals Ltd. faces heightened financing risk because the October 2025 Purchase Agreement restricts variable rate financings until April 12, 2026, and equity financings below the October 2025 unit price until June 2, 2026. These covenants, combined with the October Purchasers’ 25% participation right, may limit its ability to secure timely, acceptable funding, potentially forcing program delays or terminations that could materially harm its business and financial condition.
The average QNRX stock price target is $37.50, implying 485.02% upside potential.
To learn more about Quoin Pharmaceuticals Ltd’s risk factors, click here.